0
0
NEW DELHI — In a major strategic pivot aimed at transforming India from the “pharmacy of the world” into a global powerhouse for high-tech biological medicines, the Union Government has officially launched the Biopharma SHAKTI scheme. Announced by the Minister of State for Chemicals and Fertilizers, Smt. Anupriya Patel, in the Rajya Sabha on March 10, 2026, the initiative commits ₹10,000 crore over the next five years to foster a domestic ecosystem for biologics and biosimilars.
The move comes as India faces a critical “epidemiological transition,” where non-communicable diseases (NCDs) like cancer and diabetes now account for nearly 60% to 65% of all deaths in the country. By incentivizing domestic innovation, the government aims to slash the high cost of life-saving biological treatments, which have historically remained out of reach for most Indian patients.
A Shield Against Chronic Illness
Unlike traditional “small-molecule” drugs (like aspirin) which are chemically synthesized, biologics are complex medicines derived from living organisms. While they are highly effective for treating aggressive cancers and autoimmune disorders, their manufacturing complexity makes them prohibitively expensive.
According to the Global Burden of Disease (GBD) 2025 data, the prevalence of diabetes in India has surged to nearly 90 million adults. “Biologic medicines are no longer a luxury; they are the key to longevity and quality of life,” stated Smt. Anupriya Patel in her written reply. The SHAKTI (Strategy for Healthcare Advancement through Knowledge, Technology, and Innovation) scheme is designed to ensure these “frontier” medicines are manufactured at home.
Key Pillars of the SHAKTI Scheme:
-
Manufacturing Hubs: Scaling up domestic production to reduce reliance on expensive imports.
-
Infrastructure & Talent: Establishing three new National Institutes of Pharmaceutical Education & Research (NIPERs) and upgrading seven existing ones to create a specialized workforce.
-
Clinical Research: Building a network of 1,000 accredited clinical trial sites to accelerate the validation of new therapies.
-
Regulatory Reform: Strengthening the Central Drugs Standard Control Organisation (CDSCO) with a dedicated “Scientific Review Cadre” to speed up approvals without compromising safety.
-
Startup Support: Providing early-stage innovation funding and structured equity to help biotech startups bridge the “valley of death” between laboratory concept and market-ready product.
Expert Perspectives: From Volume to Value
Industry veterans have hailed the scheme as a “historic shift.” Kiran Mazumdar-Shaw, Executive Chairperson of Biocon Limited, noted on social media that the investment positions biopharma among India’s most strategic frontier sectors.
“This is about moving India up the value chain—from volume-led growth to innovation-driven leadership,” says Dr. Suchitra K. Ella, co-founder of Bharat Biotech and Vice President of CII. She emphasized that the creation of a 1,000-site clinical trial network addresses a long-standing “talent bottleneck” that has historically limited original drug discovery in India.
However, some experts urge a balanced view. While the funding is significant, the cost of bringing a single biosimilar to market can exceed $100 million (approx. ₹830 crore). Manoj Joshi, Secretary of the Department of Pharmaceuticals, acknowledged that while the scheme provides a vital anchor, additional grants for expensive Phase III clinical trials are still under review to ensure small innovators aren’t squeezed out by high development costs.
What This Means for Patients
For the average consumer, the most tangible impact of Biopharma SHAKTI will be the increased availability of biosimilars—products highly similar to original biologics but significantly more affordable.
Currently, a single course of targeted immunotherapy for cancer can cost several lakhs of rupees. By fostering a “globally competitive domestic ecosystem,” the government expects prices to drop as domestic competition increases, similar to how India revolutionized the global market for generic HIV and heart medications two decades ago.
Challenges and Limitations
Despite the optimism, the road ahead contains hurdles. Peer-reviewed studies in journals like The Lancet Regional Health have highlighted that India’s regulatory environment, while improving, still faces staffing shortages at the CDSCO.
“Reducing the number of days for regulatory approvals is a double-edged sword,” warns a public health researcher. “It must be balanced with rigorous post-marketing surveillance to ensure that the rapid entry of new biologics does not compromise patient safety in the long term.” Furthermore, there are calls from civil society to eliminate unnecessary animal studies in biosimilar development to further lower costs—a point currently under debate within the CDSCO’s 2025-26 draft guidelines.
Reference Section
-
PIB Delhi: “Bio Pharma SHAKTI scheme,” Posted 10 MAR 2026. [Release ID: 2237416].
Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
